Standard BioTools Inc. Payments of Debt Issuance Costs
Standard BioTools Inc. (LAB) reported Payments of Debt Issuance Costs of $0 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2021-08-06
- Standard BioTools Inc. payments of debt issuance costs for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. payments of debt issuance costs for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. payments of debt issuance costs for the quarter ending 2020-06-30 was $18.00K, a 20.00% increase year-over-year.
- Standard BioTools Inc. payments of debt issuance costs for the quarter ending 2020-03-31 was $357.00K.
- Standard BioTools Inc. payments of debt issuance costs for fiscal 2018 was $2.86M.
- Standard BioTools Inc. payments of debt issuance costs for fiscal 2017 was $0.00.
- Standard BioTools Inc. payments of debt issuance costs for fiscal 2016 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2020-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $375.00K 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $357.00K 10-Q · filed 2021-05-07 | |||
| 2019-09-30 | $113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $128.00K derived: sum of 2 quarters · filed 2019-11-08 | $128.00K 10-Q · filed 2019-11-08 | $211.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $15.00K 10-Q · filed 2019-08-07 | $98.00K derived: sum of 3 quarters · filed 2019-08-07 | $239.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | $83.00K derived: sum of 2 quarters · filed 2019-05-07 | $224.00K derived: sum of 3 quarters · filed 2019-11-08 | $2.78M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $224.00K derived: sum of 2 quarters · filed 2019-11-08 | $2.78M derived: sum of 3 quarters · filed 2019-11-08 | $2.86M 10-K · filed 2019-03-18 |
| 2018-09-30 | $141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.70M derived: sum of 2 quarters · filed 2019-11-08 | $2.78M 10-Q · filed 2019-11-08 | $2.78M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.64M 10-Q · filed 2019-08-07 | $2.64M derived: sum of 3 quarters · filed 2019-08-07 | $2.64M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $82.00K 10-Q · filed 2019-05-07 | $82.00K derived: sum of 2 quarters · filed 2019-05-07 | $82.00K derived: sum of 3 quarters · filed 2019-05-07 | $82.00K derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $0.00 derived: sum of 2 quarters · filed 2019-03-18 | $0.00 derived: sum of 3 quarters · filed 2019-03-18 | $0.00 10-K · filed 2019-03-18 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |